|By PR Newswire||
|September 3, 2014 07:30 AM EDT||
NEW YORK, Sept. 3, 2014 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD) ("Relmada" or the "Company"), today announced it will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2014, at The Palace Hotel in New York City.
Sergio Traversa, CEO of Relmada Therapeutics, will provide an update on the Company during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.
Event: 16th Annual Rodman & Renshaw Global Investment Conference
Date: September 10, 2014
Time: 2:05 p.m. (Eastern Time)
Location: Kennedy II (4th Floor); the Palace Hotel in New York City
If you are an institutional investor, and would like to attend the Relmada's presentation, please click on the following link (www.rodm.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Sergio Traversa.
The Relmada presentation will also be available via a live webcast. To access the webcast, please visit www.rodm.com or http://wsw.com/webcast/rrshq24/rlmd. The webcast replay will remain available for 90 days following the live presentation.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical stage, public specialty pharmaceutical company, focused on developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at different stages of development and a deep early stage pipeline. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team with inputs from a world-class scientific advisory board. The Company's approach is expected to reduce overall clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.
About Rodman & Renshaw Conferences, LLC –
The Rodman & Renshaw Annual Global Investment Conference is an informational service and networking opportunity for companies and investors. Rodman does not prepare, review or edit the presentations and other information provided by each company, and does not take any responsibility for the accuracy or adequacy of any such information as the basis for any investment decision. Rodman is not providing any person with any investment advice through their participation in or attendance of the Conference, nor is Rodman soliciting any offers to buy or sell any security of any company.
This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Visit our website at, www.relmada.com
SOURCE Relmada Therapeutics, Inc.
May. 2, 2016 03:00 PM EDT Reads: 265
May. 2, 2016 02:45 PM EDT Reads: 1,044
May. 2, 2016 02:00 PM EDT Reads: 907
May. 2, 2016 12:30 PM EDT Reads: 1,260
May. 2, 2016 12:00 PM EDT Reads: 1,532
May. 2, 2016 11:45 AM EDT Reads: 923
May. 2, 2016 11:30 AM EDT Reads: 1,023
So, you bought into the current machine learning craze and went on to collect millions/billions of records from this promising new data source. Now, what do you do with them? Too often, the abundance of data quickly turns into an abundance of problems. How do you extract that "magic essence" from your data without falling into the common pitfalls? In her session at @ThingsExpo, Natalia Ponomareva, Software Engineer at Google, will provide tips on how to be successful in large scale machine lear...
May. 2, 2016 11:30 AM EDT Reads: 1,310
May. 2, 2016 10:00 AM EDT Reads: 2,617
May. 2, 2016 10:00 AM EDT Reads: 1,014
May. 2, 2016 09:15 AM EDT Reads: 853
May. 2, 2016 08:45 AM EDT Reads: 779
May. 2, 2016 08:45 AM EDT Reads: 657
May. 2, 2016 08:30 AM EDT Reads: 1,072
See storage differently! Storage performance problems have only gotten worse and harder to solve as applications have become largely virtualized and moved to a cloud-based infrastructure. Storage performance in a virtualized environment is not just about IOPS, it is about how well that potential performance is guaranteed to individual VMs for these apps as the number of VMs keep going up real time. In his session at 18th Cloud Expo, Dhiraj Sehgal, in product and marketing at Tintri, will discu...
May. 2, 2016 07:00 AM EDT Reads: 878